Respiratory Syncytial Virus Debate
Full Debate: Read Full DebateLord Bishop of Carlisle
Main Page: Lord Bishop of Carlisle (Bishops - Bishops)Department Debates - View all Lord Bishop of Carlisle's debates with the Department of Health and Social Care
(1 year, 2 months ago)
Lords ChamberThe hope is that there will be two effective and cost-effective vaccines, nirsevimab and the Pfizer maternal jab. Those are much more effective and give longer periods of protection than the current monthly jab—they give six months’ protection. They are open to a mass campaign, particularly for young children, who are the most at-risk group. That allows us to have a negotiation with both parties with some healthy competitive tension so that we can get the best price, because we know that either one will do the job quite well. Where we can reach a successfully negotiated outcome, we hope that will set us up either to do either a year-round programme, if it really is very cost effective, or, if it is still quite expensive, to focus on the winter months, because that is the time when young children are most at risk if they have just been born. Those negotiations are live, and I will be happy to update the House as we learn more.
My Lords, I, too, welcome the Minister’s detailed knowledge of this subject. Testing it even further, if I may, can I ask him whether His Majesty’s Government have made any assessment of the usefulness of glycolipid research in countering not only RSV but other viral illnesses, including influenza and Covid-19?
I fear I might have been taken to the limit of my knowledge. I would like to think I know when to stop and to offer to follow up in writing.